Radium-223 chloride granted FDA Fast Track designation for treatment of CRPC

[News]

Algeta ASA, a company focused on the development of novel targeted cancer therapeutics, today announced that radium-223 chloride has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases.

More... (http://www.news-medical.net/news/20110823/Radium-223-chloride-granted-FDA-Fast-Track-designation-for-treatment-of-CRPC.aspx)